{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:50:55Z","timestamp":1795045855780,"version":"4.10.2"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202884"],"award-info":[{"award-number":["82202884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520300"],"award-info":[{"award-number":["2024ZD0520300"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Hospitals Authority Clinical Medicine Development of special funding support","doi-asserted-by":"crossref","award":["ZLRK202302"],"award-info":[{"award-number":["ZLRK202302"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Technologies R&D Program","award":["2015BAI13B09"],"award-info":[{"award-number":["2015BAI13B09"]}]},{"name":"National Key Technologies R&D Program of China","award":["2017YFC0110904"],"award-info":[{"award-number":["2017YFC0110904"]}]},{"name":"Clinical Center for Colorectal Cancer, Capital Medical University","award":["1192070313"],"award-info":[{"award-number":["1192070313"]}],"id":[{"id":"https:\/\/ror.org\/013xs5b60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01732-z","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:44:17Z","timestamp":1756813457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives"],"prefix":"10.1186","volume":"18","author":[{"given":"Shengbo","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","volume":"86","author":"S Gaikwad","year":"2022","unstructured":"Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86:137\u201350. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.014.","journal-title":"Semin Cancer Biol"},{"key":"1732_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-024-02028-3","volume":"9","author":"C Zhu","year":"2024","unstructured":"Zhu C, Liu C, Wu Q, Sheng T, Zhou R, Ren E, Zhang R, Zhao Z, Shi J, Shen X, et al. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors. Signal Transduct Target Ther. 2024;9:307. https:\/\/doi.org\/10.1038\/s41392-024-02028-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1732_CR3","doi-asserted-by":"publisher","first-page":"1462221","DOI":"10.3389\/fimmu.2024.1462221","volume":"15","author":"MJ Newman","year":"2024","unstructured":"Newman MJ. Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy. Front Immunol. 2024;15:1462221. https:\/\/doi.org\/10.3389\/fimmu.2024.1462221.","journal-title":"Front Immunol"},{"key":"1732_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122419","volume":"340","author":"Z Chen","year":"2024","unstructured":"Chen Z, Hu T, Zhou J, Gu X, Chen S, Qi Q, Wang L. Overview of tumor immunotherapy based on approved drugs. Life Sci. 2024;340: 122419. https:\/\/doi.org\/10.1016\/j.lfs.2024.122419.","journal-title":"Life Sci"},{"key":"1732_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020;78:1019\u201333. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.034.","journal-title":"Mol Cell"},{"key":"1732_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890166","volume":"13","author":"R Bai","year":"2022","unstructured":"Bai R, Cui J. Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. Front Immunol. 2022;13: 890166. https:\/\/doi.org\/10.3389\/fimmu.2022.890166.","journal-title":"Front Immunol"},{"key":"1732_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101733","volume":"66","author":"R Ahn","year":"2023","unstructured":"Ahn R, Cui Y, White FM. Antigen discovery for the development of cancer immunotherapy. Semin Immunol. 2023;66: 101733. https:\/\/doi.org\/10.1016\/j.smim.2023.101733.","journal-title":"Semin Immunol"},{"key":"1732_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. 2020;38:454\u201372. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.013.","journal-title":"Cancer Cell"},{"key":"1732_CR9","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020.","journal-title":"Cell"},{"key":"1732_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.13249","volume":"318","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Jung S, Balko JM, Johnson DB. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. Immunol Rev. 2023;318:157\u201366. https:\/\/doi.org\/10.1111\/imr.13249.","journal-title":"Immunol Rev"},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9:543\u201353. https:\/\/doi.org\/10.1016\/j.trecan.2023.04.002.","journal-title":"Trends Cancer"},{"key":"1732_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12943-024-02141-5","volume":"23","author":"R Yang","year":"2024","unstructured":"Yang R, Cui J. Advances and applications of RNA vaccines in tumor treatment. Mol Cancer. 2024;23:226. https:\/\/doi.org\/10.1186\/s12943-024-02141-5.","journal-title":"Mol Cancer"},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22:141. https:\/\/doi.org\/10.1186\/s12943-023-01844-5.","journal-title":"Mol Cancer"},{"key":"1732_CR14","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K, Sun W, Zheng X, Qi J, Jin W, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun. 2023;14:6389. https:\/\/doi.org\/10.1038\/s41467-023-42010-1.","journal-title":"Nat Commun"},{"key":"1732_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8:450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1732_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","volume":"21","author":"J Budczies","year":"2024","unstructured":"Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C, Schwab C, Allgauer M, Ahadova A, Kloor M, et al. Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol. 2024;21:725\u201342. https:\/\/doi.org\/10.1038\/s41571-024-00932-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1732_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","volume":"25","author":"TE Keenan","year":"2019","unstructured":"Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389\u2013402. https:\/\/doi.org\/10.1038\/s41591-019-0382-x.","journal-title":"Nat Med"},{"key":"1732_CR18","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377:2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"key":"1732_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science"},{"key":"1732_CR20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"1732_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","volume":"15","author":"LM Sholl","year":"2020","unstructured":"Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, et al. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15:1409\u201324. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.019.","journal-title":"J Thorac Oncol"},{"key":"1732_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02420-y","author":"F Huber","year":"2024","unstructured":"Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, Bobisse S, Chiffelle J, Gehert T, Muller M, et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02420-y.","journal-title":"Nat Biotechnol"},{"key":"1732_CR23","doi-asserted-by":"publisher","unstructured":"Hu C, Zhao L, Liu W, Fan S, Liu J, Liu Y, Liu X, Shu L, Liu X, Liu P, et al. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer. 2021;9.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003773.","DOI":"10.1136\/jitc-2021-003773"},{"key":"1732_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7: 100336. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100336.","journal-title":"ESMO Open"},{"key":"1732_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"1732_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4049\/jimmunol.1701413","volume":"200","author":"AE Zamora","year":"2018","unstructured":"Zamora AE, Crawford JC, Thomas PG. Hitting the Target: How T Cells Detect and Eliminate Tumors. J Immunol. 2018;200:392\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1701413.","journal-title":"J Immunol"},{"key":"1732_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(17)30516-8.","journal-title":"Lancet Oncol."},{"key":"1732_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, Boland GM. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512. https:\/\/doi.org\/10.1038\/s41568-024-00705-7.","journal-title":"Nat Rev Cancer"},{"key":"1732_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128. https:\/\/doi.org\/10.1186\/s12943-019-1055-6.","journal-title":"Mol Cancer"},{"key":"1732_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8:9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1732_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.tcb.2019.01.003","volume":"29","author":"I Vitale","year":"2019","unstructured":"Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends Cell Biol. 2019;29:396\u2013416. https:\/\/doi.org\/10.1016\/j.tcb.2019.01.003.","journal-title":"Trends Cell Biol"},{"key":"1732_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdy495.","journal-title":"Ann Oncol"},{"key":"1732_CR33","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413\u201321. https:\/\/doi.org\/10.1172\/JCI80008.","journal-title":"J Clin Invest"},{"key":"1732_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.trecan.2019.10.006","volume":"5","author":"I Catalano","year":"2019","unstructured":"Catalano I, Grassi E, Bertotti A, Trusolino L. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer. 2019;5:779\u201388. https:\/\/doi.org\/10.1016\/j.trecan.2019.10.006.","journal-title":"Trends Cancer"},{"key":"1732_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"1732_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13073-020-00729-2","volume":"12","author":"MA Wood","year":"2020","unstructured":"Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Med. 2020;12:33. https:\/\/doi.org\/10.1186\/s13073-020-00729-2.","journal-title":"Genome Med"},{"key":"1732_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.109885","volume":"188","author":"MJ Kamali","year":"2025","unstructured":"Kamali MJ, Salehi M, Fath MK. Advancing personalized immunotherapy for melanoma: Integrating immunoinformatics in multi-epitope vaccine development, neoantigen identification via NGS, and immune simulation evaluation. Comput Biol Med. 2025;188: 109885. https:\/\/doi.org\/10.1016\/j.compbiomed.2025.109885.","journal-title":"Comput Biol Med"},{"key":"1732_CR38","doi-asserted-by":"publisher","first-page":"1444327","DOI":"10.3389\/fonc.2024.1444327","volume":"14","author":"G Wagutu","year":"2024","unstructured":"Wagutu G, Gitau J, Mwangi K, Murithi M, Melly E, Harris AR, Sayed S, Ambs S, Makokha F. Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients. Front Oncol. 2024;14:1444327. https:\/\/doi.org\/10.3389\/fonc.2024.1444327.","journal-title":"Front Oncol"},{"key":"1732_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8:11. https:\/\/doi.org\/10.1186\/s13073-016-0264-5.","journal-title":"Genome Med"},{"key":"1732_CR40","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449\u201354. https:\/\/doi.org\/10.1093\/nar\/gkaa379.","journal-title":"Nucleic Acids Res"},{"key":"1732_CR41","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.170050","volume":"4","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Lyu X, Wu J, Yang X, Wu S, Zhou J, Gu X, Su Z, Chen S. TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc Open Sci. 2017;4: 170050. https:\/\/doi.org\/10.1098\/rsos.170050.","journal-title":"R Soc Open Sci"},{"key":"1732_CR42","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/bioinformatics\/btx375","volume":"33","author":"P Bais","year":"2017","unstructured":"Bais P, Namburi S, Gatti DM, Zhang X, Chuang JH. CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics. 2017;33:3110\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btx375.","journal-title":"Bioinformatics"},{"key":"1732_CR43","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1093\/bioinformatics\/btx377","volume":"33","author":"E Tappeiner","year":"2017","unstructured":"Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33:3140\u20131. https:\/\/doi.org\/10.1093\/bioinformatics\/btx377.","journal-title":"Bioinformatics"},{"key":"1732_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cels.2022.12.002","volume":"14","author":"D Gfeller","year":"2023","unstructured":"Gfeller D, Schmidt J, Croce G, Guillaume P, Bobisse S, Genolet R, Queiroz L, Cesbron J, Racle J, Harari A. Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+) T-cell epitopes. Cell Syst. 2023;14:72\u201383. https:\/\/doi.org\/10.1016\/j.cels.2022.12.002.","journal-title":"Cell Syst"},{"key":"1732_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4313","author":"B Bulik-Sullivan","year":"2018","unstructured":"Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2018. https:\/\/doi.org\/10.1038\/nbt.4313.","journal-title":"Nat Biotechnol"},{"key":"1732_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100506","volume":"22","author":"RM Pyke","year":"2023","unstructured":"Pyke RM, Mellacheruvu D, Dea S, Abbott C, Zhang SV, Phillips NA, Harris J, Bartha G, Desai S, McClory R, et al. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation. Mol Cell Proteomics. 2023;22: 100506. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100506.","journal-title":"Mol Cell Proteomics"},{"key":"1732_CR47","doi-asserted-by":"publisher","unstructured":"Wang X, Wu T, Jiang Y, Chen T, Pan D, Jin Z, Xie J, Quan L, Lyu Q. RPEMHC: improved prediction of MHC-peptide binding affinity by a deep learning approach based on residue-residue pair encoding. Bioinformatics. 2024;40. https:\/\/doi.org\/10.1093\/bioinformatics\/btad785.","DOI":"10.1093\/bioinformatics\/btad785"},{"key":"1732_CR48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s42256-025-01002-0","volume":"7","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yu J, Su Y, Shu Y, Ma E, Wang J, Jiang S, Wei C, Li D, Huang Z, et al. A unified deep framework for peptide\u2013major histocompatibility complex\u2013T cell receptor binding prediction. Nature Machine Intelligence. 2025;7:650\u201360. https:\/\/doi.org\/10.1038\/s42256-025-01002-0.","journal-title":"Nature Machine Intelligence"},{"key":"1732_CR49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s42256-023-00634-4","volume":"5","author":"X Peng","year":"2023","unstructured":"Peng X, Lei Y, Feng P, Jia L, Ma J, Zhao D, Zeng J. Characterizing the interaction conformation between T-cell receptors and epitopes with deep learning. Nature Machine Intelligence. 2023;5:395\u2013407. https:\/\/doi.org\/10.1038\/s42256-023-00634-4.","journal-title":"Nature Machine Intelligence"},{"key":"1732_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/bioinformatics\/btw674","volume":"33","author":"J Zhang","year":"2017","unstructured":"Zhang J, Mardis ER, Maher CA. INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery. Bioinformatics. 2017;33:555\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btw674.","journal-title":"Bioinformatics"},{"key":"1732_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2020.06.024","volume":"182","author":"J Vijg","year":"2020","unstructured":"Vijg J, Dong X. Pathogenic Mechanisms of Somatic Mutation and Genome Mosaicism in Aging. Cell. 2020;182:12\u201323. https:\/\/doi.org\/10.1016\/j.cell.2020.06.024.","journal-title":"Cell"},{"key":"1732_CR52","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.3390\/cancers3044191","volume":"3","author":"L Li","year":"2011","unstructured":"Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE. Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel). 2011;3:4191\u2013211. https:\/\/doi.org\/10.3390\/cancers3044191.","journal-title":"Cancers (Basel)"},{"key":"1732_CR53","doi-asserted-by":"publisher","unstructured":"Li L, Goedegebuure SP, Gillanders WE. Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017;28:xii11-xii17. https:\/\/doi.org\/10.1093\/annonc\/mdx681.","DOI":"10.1093\/annonc\/mdx681"},{"key":"1732_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14760584.2022.2012456","volume":"21","author":"G Richard","year":"2022","unstructured":"Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2022;21:173\u201384. https:\/\/doi.org\/10.1080\/14760584.2022.2012456.","journal-title":"Expert Rev Vaccines"},{"key":"1732_CR55","doi-asserted-by":"publisher","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J Immunol. 2017;199:3360\u20133368. https:\/\/doi.org\/10.4049\/jimmunol.1700893.","DOI":"10.4049\/jimmunol.1700893"},{"key":"1732_CR56","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404. https:\/\/doi.org\/10.1038\/ncomms13404.","journal-title":"Nat Commun"},{"key":"1732_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","volume":"40","author":"C Chong","year":"2022","unstructured":"Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2022;40:175\u201388. https:\/\/doi.org\/10.1038\/s41587-021-01038-8.","journal-title":"Nat Biotechnol"},{"key":"1732_CR58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41592-023-01791-5","volume":"20","author":"HM Bennett","year":"2023","unstructured":"Bennett HM, Stephenson W, Rose CM, Darmanis S. Single-cell proteomics enabled by next-generation sequencing or mass spectrometry. Nat Methods. 2023;20:363\u201374. https:\/\/doi.org\/10.1038\/s41592-023-01791-5.","journal-title":"Nat Methods"},{"key":"1732_CR59","doi-asserted-by":"publisher","unstructured":"Ade CM, Sporn MJ, Das S, Yu Z, Hanada KI, Qi YA, Maity T, Zhang X, Guha U, Andresson T, et al. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-007097.","DOI":"10.1136\/jitc-2023-007097"},{"key":"1732_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109542","volume":"120","author":"X Zhang","year":"2019","unstructured":"Zhang X, Qi Y, Zhang Q, Liu W. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. Biomed Pharmacother. 2019;120: 109542. https:\/\/doi.org\/10.1016\/j.biopha.2019.109542.","journal-title":"Biomed Pharmacother"},{"key":"1732_CR61","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020;10:1808\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0522.","journal-title":"Cancer Discov"},{"key":"1732_CR62","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.1038\/s41467-024-49782-0","volume":"15","author":"L Yang","year":"2024","unstructured":"Yang L, Ou YN, Wu BS, Liu WS, Deng YT, He XY, Chen YL, Kang J, Fei CJ, Zhu Y, et al. Large-scale whole-exome sequencing analyses identified protein-coding variants associated with immune-mediated diseases in 350,770 adults. Nat Commun. 2024;15:5924. https:\/\/doi.org\/10.1038\/s41467-024-49782-0.","journal-title":"Nat Commun"},{"key":"1732_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.415","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W, Wang R, Fang H, Ma X, Li D, Liu T, Chen Z, Wang K, Hao S, Yu Z, et al. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing. Clin Transl Med. 2021;11: e415. https:\/\/doi.org\/10.1002\/ctm2.415.","journal-title":"Clin Transl Med"},{"key":"1732_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100936","volume":"40","author":"E Krebs","year":"2024","unstructured":"Krebs E, Weymann D, Ho C, Bosdet I, Laskin J, Lim HJ, Yip S, Karsan A, Hanna TP, Pollard S, et al. Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study. Lancet Reg Health Am. 2024;40: 100936. https:\/\/doi.org\/10.1016\/j.lana.2024.100936.","journal-title":"Lancet Reg Health Am"},{"key":"1732_CR65","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res. 2021;27:4685\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","journal-title":"Clin Cancer Res"},{"key":"1732_CR66","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, et al. Targeting public neoantigens for cancer immunotherapy. Nat Cancer. 2021;2:487\u201397. https:\/\/doi.org\/10.1038\/s43018-021-00210-y.","journal-title":"Nat Cancer"},{"key":"1732_CR67","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139. https:\/\/doi.org\/10.1126\/science.aaf1490.","journal-title":"Science"},{"key":"1732_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672677","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang P, Chen Y, Wang C. Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy. Front Oncol. 2021;11: 672677. https:\/\/doi.org\/10.3389\/fonc.2021.672677.","journal-title":"Front Oncol"},{"key":"1732_CR69","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3389\/fimmu.2019.01392","volume":"10","author":"A Garcia-Garijo","year":"2019","unstructured":"Garcia-Garijo A, Fajardo CA, Gros A. Determinants for Neoantigen Identification Front Immunol. 2019;10:1392. https:\/\/doi.org\/10.3389\/fimmu.2019.01392.","journal-title":"Determinants for Neoantigen Identification Front Immunol"},{"key":"1732_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2021.02.023","volume":"506","author":"Y Wang","year":"2021","unstructured":"Wang Y, Shi T, Song X, Liu B, Wei J. Gene fusion neoantigens: Emerging targets for cancer immunotherapy. Cancer Lett. 2021;506:45\u201354. https:\/\/doi.org\/10.1016\/j.canlet.2021.02.023.","journal-title":"Cancer Lett"},{"key":"1732_CR71","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, Reading JL, Joshi K, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385. https:\/\/doi.org\/10.1038\/s41586-019-1032-7.","journal-title":"Nature"},{"key":"1732_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1302631","volume":"6","author":"EM Inderberg","year":"2017","unstructured":"Inderberg EM, Walchli S, Myhre MR, Trachsel S, Almasbak H, Kvalheim G, Gaudernack G. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology. 2017;6: e1302631. https:\/\/doi.org\/10.1080\/2162402X.2017.1302631.","journal-title":"Oncoimmunology"},{"key":"1732_CR73","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577\u201381. https:\/\/doi.org\/10.1038\/nature13988.","journal-title":"Nature"},{"key":"1732_CR74","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 2018;9:14. https:\/\/doi.org\/10.3389\/fimmu.2018.00014.","journal-title":"Front Immunol"},{"key":"1732_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109696","volume":"36","author":"YJ Lu","year":"2021","unstructured":"Lu YJ, Barreira-Silva P, Boyce S, Powers J, Cavallo K, Behar SM. CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell Rep. 2021;36: 109696. https:\/\/doi.org\/10.1016\/j.celrep.2021.109696.","journal-title":"Cell Rep"},{"key":"1732_CR76","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509\u201321. https:\/\/doi.org\/10.1002\/jcp.27782.","journal-title":"J Cell Physiol"},{"key":"1732_CR77","doi-asserted-by":"publisher","first-page":"1473145","DOI":"10.3389\/fimmu.2024.1473145","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang S, Huang C, Li Y, Li Z, Zhu Y, Yang L, Hu H, Sun Q, Liu M, Cao S. Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening. Front Immunol. 2024;15:1473145. https:\/\/doi.org\/10.3389\/fimmu.2024.1473145.","journal-title":"Front Immunol"},{"key":"1732_CR78","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41467-024-46367-9","volume":"15","author":"JP Finnigan","year":"2024","unstructured":"Finnigan JP, Newman JH, Patskovsky Y, Patskovska L, Ishizuka AS, Lynn GM, Seder RA, Krogsgaard M, Bhardwaj N. Structural basis for self-discrimination by neoantigen-specific TCRs. Nat Commun. 2024;15:2140. https:\/\/doi.org\/10.1038\/s41467-024-46367-9.","journal-title":"Nat Commun"},{"key":"1732_CR79","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Torngren T, Kvist A, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8:1738. https:\/\/doi.org\/10.1038\/s41467-017-01460-0.","journal-title":"Nat Commun"},{"key":"1732_CR80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41467-022-29342-0","volume":"2022","author":"JS Holm","year":"1935","unstructured":"Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat Commun. 1935;2022:13. https:\/\/doi.org\/10.1038\/s41467-022-29342-0.","journal-title":"Nat Commun"},{"key":"1732_CR81","doi-asserted-by":"publisher","unstructured":"Veatch JR, Singhi N, Srivastava S, Szeto JL, Jesernig B, Stull SM, Fitzgibbon M, Sarvothama M. Yechan-Gunja, S.; James, S.E.; et al. A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI144195.","DOI":"10.1172\/JCI144195"},{"key":"1732_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217427","volume":"611","author":"P Jin","year":"2024","unstructured":"Jin P, Shen J, Zhao M, Yu J, Jin W, Jiang G, Li Z, He M, Liu X, Wu S, et al. Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy. Cancer Lett. 2024;611: 217427. https:\/\/doi.org\/10.1016\/j.canlet.2024.217427.","journal-title":"Cancer Lett"},{"key":"1732_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114843","volume":"159","author":"A Yang","year":"2025","unstructured":"Yang A, Zhou M, Gao Y, Zhang Y. Mechanisms of CD8(+) T cell exhaustion and its clinical significance in prognosis of anti-tumor therapies: A review. Int Immunopharmacol. 2025;159: 114843. https:\/\/doi.org\/10.1016\/j.intimp.2025.114843.","journal-title":"Int Immunopharmacol"},{"key":"1732_CR84","doi-asserted-by":"publisher","unstructured":"Zhong T, Sun S, Zhao M, Zhang B, Xiong H. The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity. Cancer Biol Med. 2025;22. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0628.","DOI":"10.20892\/j.issn.2095-3941.2024.0628"},{"key":"1732_CR85","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2:1001\u201312. https:\/\/doi.org\/10.1038\/s42255-020-00280-9.","journal-title":"Nat Metab"},{"key":"1732_CR86","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu J, Rutella S. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia. Blood. 2024;143:2689\u2013700. https:\/\/doi.org\/10.1182\/blood.2023019961.","journal-title":"Blood"},{"key":"1732_CR87","doi-asserted-by":"publisher","first-page":"1548234","DOI":"10.3389\/fimmu.2025.1548234","volume":"16","author":"R Nair","year":"2025","unstructured":"Nair R, Somasundaram V, Kuriakose A, Krishn SR, Raben D, Salazar R, Nair P. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies. Front Immunol. 2025;16:1548234. https:\/\/doi.org\/10.3389\/fimmu.2025.1548234.","journal-title":"Front Immunol"},{"key":"1732_CR88","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"key":"1732_CR89","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1186\/s12967-024-05732-4","volume":"22","author":"G Li","year":"2024","unstructured":"Li G, Wu T, Li H, Wei C, Sun Y, Gao P, Huang X, Liu Z, Li J, Wang Y, et al. Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma. J Transl Med. 2024;22:966. https:\/\/doi.org\/10.1186\/s12967-024-05732-4.","journal-title":"J Transl Med"},{"key":"1732_CR90","doi-asserted-by":"publisher","unstructured":"Kang S, Mansurov A, Kurtanich T, Chun HR, Slezak AJ, Volpatti LR, Chang K, Wang T, Alpar A,; Refvik KC, et al. Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity. Sci Adv. 2023;9:eadh9879. https:\/\/doi.org\/10.1126\/sciadv.adh9879.","DOI":"10.1126\/sciadv.adh9879"},{"key":"1732_CR91","doi-asserted-by":"publisher","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9. https:\/\/doi.org\/10.1136\/jitc-2021-003894.","DOI":"10.1136\/jitc-2021-003894"},{"key":"1732_CR92","doi-asserted-by":"publisher","unstructured":"Merino A, Brunstein CC, Shanley R, Rashid F, Wangen R, Bachanova V, Juckett M, Maakaron J, Felices M, Weisdorf D, et al. N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial. Transplant Cell Ther. 2024;30:1206 e1201\u20131206 e1212. https:\/\/doi.org\/10.1016\/j.jtct.2024.09.023.","DOI":"10.1016\/j.jtct.2024.09.023"},{"key":"1732_CR93","doi-asserted-by":"publisher","unstructured":"Xu T, Fang Y, Gu Y, Xu D, Hu T, Yu T, Xu YY, Shen HY, Ma P, Shu Y. HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1\/JAK1\/FGL1 axis in lung adenocarcinoma. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-010077.","DOI":"10.1136\/jitc-2024-010077"},{"key":"1732_CR94","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1158\/2159-8290.CD-20-1145","volume":"12","author":"JM Salmon","year":"2022","unstructured":"Salmon JM, Todorovski I, Stanley KL, Bruedigam C, Kearney CJ, Martelotto LG, Rossello F, Semple T, Arnau GM, Zethoven M, et al. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discov. 2022;12:1560\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1145.","journal-title":"Cancer Discov"},{"key":"1732_CR95","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","volume":"14","author":"A Goyal","year":"2023","unstructured":"Goyal A, Bauer J, Hey J, Papageorgiou DN, Stepanova E, Daskalakis M, Scheid J, Dubbelaar M, Klimovich B, Schwarz D, et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023;14:6731. https:\/\/doi.org\/10.1038\/s41467-023-42417-w.","journal-title":"Nat Commun"},{"key":"1732_CR96","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-024-03798-z","volume":"73","author":"Z Mai","year":"2024","unstructured":"Mai Z, Kongjia L, Wang X, Xie X, Pang L, Yang H, Wen J, Fu J. Impaired TGF-beta signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy. Cancer Immunol Immunother. 2024;73:225. https:\/\/doi.org\/10.1007\/s00262-024-03798-z.","journal-title":"Cancer Immunol Immunother"},{"key":"1732_CR97","doi-asserted-by":"publisher","first-page":"1434118","DOI":"10.3389\/fimmu.2024.1434118","volume":"15","author":"Y Han","year":"2024","unstructured":"Han Y, Dong C, Hu M, Wang X, Wang G. Unlocking the adenosine receptor mechanism of the tumour immune microenvironment. Front Immunol. 2024;15:1434118. https:\/\/doi.org\/10.3389\/fimmu.2024.1434118.","journal-title":"Front Immunol"},{"key":"1732_CR98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20:203\u201317. https:\/\/doi.org\/10.1038\/s41568-020-0246-1.","journal-title":"Nat Rev Cancer"},{"key":"1732_CR99","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313\u201322. https:\/\/doi.org\/10.1038\/nrc.2018.6.","journal-title":"Nat Rev Cancer"},{"key":"1732_CR100","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11:1395. https:\/\/doi.org\/10.1038\/s41467-020-15229-5.","journal-title":"Nat Commun"},{"key":"1732_CR101","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","volume":"30","author":"K Ye","year":"2022","unstructured":"Ye K, Li F, Wang R, Cen T, Liu S, Zhao Z, Li R, Xu L, Zhang G, Xu Z, et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ. Mol Ther. 2022;30:3658\u201376. https:\/\/doi.org\/10.1016\/j.ymthe.2022.06.010.","journal-title":"Mol Ther"},{"key":"1732_CR102","doi-asserted-by":"publisher","unstructured":"Gogenur M, Balsevicius L, Bulut M, Colak N, Justesen TF, Fiehn AK, Jensen MB, Host-Rasmussen K, Cappelen B, Gaggar S, et al. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1\/2 clinical trial. J Immunother Cancer. 2023;11.\u00a0https:\/\/doi.org\/10.1136\/jitc-2023-006774.","DOI":"10.1136\/jitc-2023-006774"},{"key":"1732_CR103","doi-asserted-by":"publisher","unstructured":"Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D'Alessio F, Molsa R, Stigzelius V, et al. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcgamma and Fcalpha receptors. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2023-008342.","DOI":"10.1136\/jitc-2023-008342"},{"key":"1732_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102225","volume":"35","author":"H Hu","year":"2024","unstructured":"Hu H, Tang L, Zhao Y, Cheng J, Huang M, You Y, Zou P, Lei Q, Zhu X, Guo AY. Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies. Mol Ther Nucleic Acids. 2024;35: 102225. https:\/\/doi.org\/10.1016\/j.omtn.2024.102225.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1732_CR105","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.semcancer.2025.01.008","volume":"110","author":"T Jiang","year":"2025","unstructured":"Jiang T, Jin H, Ji X, Zheng X, Xu CX, Zhang PJ. Drivers of centrosome abnormalities: Senescence progression and tumor immune escape. Semin Cancer Biol. 2025;110:56\u201364. https:\/\/doi.org\/10.1016\/j.semcancer.2025.01.008.","journal-title":"Semin Cancer Biol"},{"key":"1732_CR106","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-025-02276-z","volume":"24","author":"K Ranjan","year":"2025","unstructured":"Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, Scallo F, Gianino N, Ferrone S, Schalper KA. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer. 2025;24:80. https:\/\/doi.org\/10.1186\/s12943-025-02276-z.","journal-title":"Mol Cancer"},{"key":"1732_CR107","doi-asserted-by":"publisher","unstructured":"Mosca L, de Angelis A, Ronchi A, De Chiara A, Fazioli F, Ruosi C, Altucci L, Conte M, de Nigris F. Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14143414.","DOI":"10.3390\/cancers14143414"},{"key":"1732_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.010","volume":"103","author":"L Yao","year":"2019","unstructured":"Yao L, Zhou L, Xuan Y, Zhang P, Wang X, Wang T, Meng T, Xue Y, Ma X, Shah AS, et al. The proteasome activator REGgamma counteracts immunoproteasome expression and autoimmunity. J Autoimmun. 2019;103: 102282. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.010.","journal-title":"J Autoimmun"},{"key":"1732_CR109","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-15710-1","volume":"2020","author":"SA Overall","year":"1909","unstructured":"Overall SA, Toor JS, Hao S, Yarmarkovich M, Sara MOR, Morozov GI, Nguyen S, Japp AS, Gonzalez N, Moschidi D, et al. High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange. Nat Commun. 1909;2020:11. https:\/\/doi.org\/10.1038\/s41467-020-15710-1.","journal-title":"Nat Commun"},{"key":"1732_CR110","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/imr.13330","volume":"323","author":"B Mishra","year":"2024","unstructured":"Mishra B, Ivashkiv LB. Interferons and epigenetic mechanisms in training, priming and tolerance of monocytes and hematopoietic progenitors. Immunol Rev. 2024;323:257\u201375. https:\/\/doi.org\/10.1111\/imr.13330.","journal-title":"Immunol Rev"},{"key":"1732_CR111","doi-asserted-by":"publisher","first-page":"1270325","DOI":"10.3389\/fendo.2023.1270325","volume":"14","author":"MA Russell","year":"2023","unstructured":"Russell MA, Richardson SJ, Morgan NG. The role of the interferon\/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes. Front Endocrinol (Lausanne). 2023;14:1270325. https:\/\/doi.org\/10.3389\/fendo.2023.1270325.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1732_CR112","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1038\/s41467-021-27331-3","volume":"12","author":"TY Song","year":"2021","unstructured":"Song TY, Long M, Zhao HX, Zou MW, Fan HJ, Liu Y, Geng CL, Song MF, Liu YF, Chen JY, et al. Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nat Commun. 2021;12:7003. https:\/\/doi.org\/10.1038\/s41467-021-27331-3.","journal-title":"Nat Commun"},{"key":"1732_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114731","volume":"157","author":"S Wang","year":"2025","unstructured":"Wang S, Sun Z, Wang C, Zhang A, Zhang C, Hou S, Lin N, Li Q. The JAK1\/STAT3 pathway mediates the effects of SERPINH1 on glioma EMT. Int Immunopharmacol. 2025;157: 114731. https:\/\/doi.org\/10.1016\/j.intimp.2025.114731.","journal-title":"Int Immunopharmacol"},{"key":"1732_CR114","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","volume":"25","author":"W Yang","year":"2019","unstructured":"Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767\u201375. https:\/\/doi.org\/10.1038\/s41591-019-0434-2.","journal-title":"Nat Med"},{"key":"1732_CR115","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12967-024-05529-5","volume":"22","author":"B Gao","year":"2024","unstructured":"Gao B, Wang Y, Zhang X, Jiang H, Han F, Li C, Lu S. Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma. J Transl Med. 2024;22:730. https:\/\/doi.org\/10.1186\/s12967-024-05529-5.","journal-title":"J Transl Med"},{"key":"1732_CR116","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207\u201311. https:\/\/doi.org\/10.1126\/science.aad0095.","journal-title":"Science"},{"key":"1732_CR117","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"key":"1732_CR118","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","journal-title":"Nature"},{"key":"1732_CR119","doi-asserted-by":"publisher","unstructured":"Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020;183:347\u2013362 e324. https:\/\/doi.org\/10.1016\/j.cell.2020.08.053.","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"1732_CR120","doi-asserted-by":"publisher","unstructured":"Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, Dephoure N, Clement CC, Santambrogio L, Zhou XK, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI138740.","DOI":"10.1172\/JCI138740"},{"key":"1732_CR121","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","volume":"29","author":"M Thibaudin","year":"2023","unstructured":"Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial. Nat Med. 2023;29:2087\u201398. https:\/\/doi.org\/10.1038\/s41591-023-02497-z.","journal-title":"Nat Med"},{"key":"1732_CR122","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1158\/2326-6066.CIR-17-0630","volume":"6","author":"D Ji","year":"2018","unstructured":"Ji D, Yi H, Zhang D, Zhan T, Li Z, Li M, Jia J, Qiao M, Xia J, Zhai Z, et al. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. Cancer Immunol Res. 2018;6:1401\u201316. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0630.","journal-title":"Cancer Immunol Res"},{"key":"1732_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01033-x","author":"JCM Wan","year":"2025","unstructured":"Wan JCM, Sasieni P, Rosenfeld N. Promises and pitfalls of multi-cancer early detection using liquid biopsy tests. Nat Rev Clin Oncol. 2025. https:\/\/doi.org\/10.1038\/s41571-025-01033-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1732_CR124","doi-asserted-by":"publisher","first-page":"1903410","DOI":"10.1002\/advs.201903410","volume":"7","author":"Q Jia","year":"2020","unstructured":"Jia Q, Chiu L, Wu S, Bai J, Peng L, Zheng L, Zang R, Li X, Yuan B, Gao Y, et al. Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer. Adv Sci (Weinh). 2020;7:1903410. https:\/\/doi.org\/10.1002\/advs.201903410.","journal-title":"Adv Sci (Weinh)"},{"key":"1732_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672356","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol. 2021;12: 672356. https:\/\/doi.org\/10.3389\/fimmu.2021.672356.","journal-title":"Front Immunol"},{"key":"1732_CR126","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"F Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019;129:2056\u201370. https:\/\/doi.org\/10.1172\/JCI99538.","journal-title":"J Clin Invest"},{"key":"1732_CR127","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13073-021-00872-4","volume":"13","author":"L Li","year":"2021","unstructured":"Li L, Zhang X, Wang X, Kim SW, Herndon JM, Becker-Hapak MK, Carreno BM, Myers NB, Sturmoski MA, McLellan MD, et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Med. 2021;13:56. https:\/\/doi.org\/10.1186\/s13073-021-00872-4.","journal-title":"Genome Med"},{"key":"1732_CR128","doi-asserted-by":"publisher","unstructured":"Chiapperino L, Graber N, Panese F. A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies. Soc Stud Sci. 2024:3063127241303720. https:\/\/doi.org\/10.1177\/03063127241303720.","DOI":"10.1177\/03063127241303720"},{"key":"1732_CR129","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","volume":"30","author":"TJ Alban","year":"2024","unstructured":"Alban TJ, Riaz N, Parthasarathy P, Makarov V, Kendall S, Yoo SK, Shah R, Weinhold N, Srivastava R, Ma X, et al. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Nat Med. 2024;30:3209\u201322. https:\/\/doi.org\/10.1038\/s41591-024-03240-y.","journal-title":"Nat Med"},{"key":"1732_CR130","doi-asserted-by":"publisher","first-page":"1368749","DOI":"10.3389\/fimmu.2024.1368749","volume":"15","author":"Y Qin","year":"2024","unstructured":"Qin Y, Huo M, Liu X, Li SC. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy. Front Immunol. 2024;15:1368749. https:\/\/doi.org\/10.3389\/fimmu.2024.1368749.","journal-title":"Front Immunol"},{"key":"1732_CR131","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122\u201339. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003.","journal-title":"Trends Cancer"},{"key":"1732_CR132","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.7150\/ijbs.76281","volume":"18","author":"Z Liu","year":"2022","unstructured":"Liu Z, Lv J, Dang Q, Liu L, Weng S, Wang L, Zhou Z, Kong Y, Li H, Han Y, et al. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Int J Biol Sci. 2022;18:5607\u201323. https:\/\/doi.org\/10.7150\/ijbs.76281.","journal-title":"Int J Biol Sci"},{"key":"1732_CR133","doi-asserted-by":"publisher","unstructured":"Reparaz D, Aparicio B, Llopiz D, Hervas-Stubbs S, Sarobe P. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? Int J Mol Sci. 2022;23.\u00a0https:\/\/doi.org\/10.3390\/ijms23042022.","DOI":"10.3390\/ijms23042022"},{"key":"1732_CR134","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7.","journal-title":"Lancet"},{"key":"1732_CR135","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, et al. T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer Discov. 2024;14:2209\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0158.","journal-title":"Cancer Discov"},{"key":"1732_CR136","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","volume":"22","author":"C Gustafsson","year":"2004","unstructured":"Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22:346\u201353. https:\/\/doi.org\/10.1016\/j.tibtech.2004.04.006.","journal-title":"Trends Biotechnol"},{"key":"1732_CR137","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther. 2015;23:1456\u201364. https:\/\/doi.org\/10.1038\/mt.2015.103.","journal-title":"Mol Ther"},{"key":"1732_CR138","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","volume":"42","author":"P Guasp","year":"2024","unstructured":"Guasp P, Reiche C, Sethna Z, Balachandran VP. RNA vaccines for cancer: Principles to practice. Cancer Cell. 2024;42:1163\u201384. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.005.","journal-title":"Cancer Cell"},{"key":"1732_CR139","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696\u2013701. https:\/\/doi.org\/10.1038\/s41586-019-1671-8.","journal-title":"Nature"},{"key":"1732_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2021.102443","volume":"37","author":"X Yang","year":"2021","unstructured":"Yang X, Fan J, Wu Y, Ma Z, Huang J, Zhang Y, Zhou Z, Mo F, Liu X, Yuan H, et al. Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy. Nanomedicine. 2021;37: 102443. https:\/\/doi.org\/10.1016\/j.nano.2021.102443.","journal-title":"Nanomedicine"},{"key":"1732_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115928","volume":"169","author":"SI Hung","year":"2023","unstructured":"Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, et al. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomed Pharmacother. 2023;169: 115928. https:\/\/doi.org\/10.1016\/j.biopha.2023.115928.","journal-title":"Biomed Pharmacother"},{"key":"1732_CR142","doi-asserted-by":"publisher","first-page":"1104860","DOI":"10.3389\/fimmu.2023.1104860","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Xu Z, Dai X, Zhang X, Wang X. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer. Front Immunol. 2023;14:1104860. https:\/\/doi.org\/10.3389\/fimmu.2023.1104860.","journal-title":"Front Immunol"},{"key":"1732_CR143","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer. 2024;10:312\u201331. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003.","journal-title":"Trends Cancer"},{"key":"1732_CR144","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20:531\u201350. https:\/\/doi.org\/10.1038\/s41573-021-00189-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1732_CR145","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1732_CR146","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","volume":"12","author":"JH Cho","year":"2021","unstructured":"Cho JH, Okuma A, Sofjan K, Lee S, Collins JJ, Wong WW. Engineering advanced logic and distributed computing in human CAR immune cells. Nat Commun. 2021;12:792. https:\/\/doi.org\/10.1038\/s41467-021-21078-7.","journal-title":"Nat Commun"},{"key":"1732_CR147","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","volume":"37","author":"Z An","year":"2018","unstructured":"An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561\u201375. https:\/\/doi.org\/10.1038\/s41388-017-0045-7.","journal-title":"Oncogene"},{"key":"1732_CR148","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/neuonc\/now113","volume":"18","author":"E Eskilsson","year":"2016","unstructured":"Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, et al. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro Oncol. 2016;18:1644\u201355. https:\/\/doi.org\/10.1093\/neuonc\/now113.","journal-title":"Neuro Oncol"},{"key":"1732_CR149","doi-asserted-by":"publisher","unstructured":"O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"1732_CR150","doi-asserted-by":"publisher","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"1732_CR151","doi-asserted-by":"publisher","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, Roybal KT. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","DOI":"10.1126\/scitranslmed.abd8836"},{"key":"1732_CR152","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm0198-043","volume":"4","author":"B Agrawal","year":"1998","unstructured":"Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4:43\u20139. https:\/\/doi.org\/10.1038\/nm0198-043.","journal-title":"Nat Med"},{"key":"1732_CR153","first-page":"5914","volume":"44","author":"G Schulz","year":"1984","unstructured":"Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914\u201320.","journal-title":"Cancer Res"},{"key":"1732_CR154","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388:1284\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2210859.","journal-title":"N Engl J Med"},{"key":"1732_CR155","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","volume":"31","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Heitzeneder S, Mackall CL. Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell. 2017;31:476\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2017.03.002.","journal-title":"Cancer Cell"},{"key":"1732_CR156","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024;30:1013\u201322. https:\/\/doi.org\/10.1038\/s41591-024-02851-9.","journal-title":"Nat Med"},{"key":"1732_CR157","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med. 2024;30:1044\u201353. https:\/\/doi.org\/10.1038\/s41591-024-02894-y.","journal-title":"Nat Med"},{"key":"1732_CR158","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, Hales RK, Voong KR, Battafarano RJ, Jobe BA, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30:1023\u201334. https:\/\/doi.org\/10.1038\/s41591-024-02877-z.","journal-title":"Nat Med"},{"key":"1732_CR159","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:152\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03334-7.","journal-title":"Nat Med"},{"key":"1732_CR160","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","volume":"6","author":"A Poh","year":"2016","unstructured":"Poh A. First Oncolytic Viral Therapy for Melanoma. Cancer Discov. 2016;6:6. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2015-158.","journal-title":"Cancer Discov"},{"key":"1732_CR161","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01897-x.","journal-title":"Nat Med"},{"key":"1732_CR162","doi-asserted-by":"publisher","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109\u20131119 e1110.\u00a0https:\/\/doi.org\/10.1016\/j.cell.2017.08.027.","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"1732_CR163","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/mt.2015.109","volume":"23","author":"SH Park","year":"2015","unstructured":"Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, et al. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Mol Ther. 2015;23:1532\u201340. https:\/\/doi.org\/10.1038\/mt.2015.109.","journal-title":"Mol Ther"},{"key":"1732_CR164","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99\u2013102. https:\/\/doi.org\/10.1038\/nature10358.","journal-title":"Nature"},{"key":"1732_CR165","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","volume":"386","author":"J Gallego Perez-Larraya","year":"2022","unstructured":"Gallego Perez-Larraya J, Garcia-Moure M, Labiano S, Patino-Garcia A, Dobbs J, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, Puigdelloses M, et al. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022;386:2471\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2202028.","journal-title":"N Engl J Med"},{"key":"1732_CR166","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1215\/S1152851705000074","volume":"7","author":"EK Hellums","year":"2005","unstructured":"Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 2005;7:213\u201324. https:\/\/doi.org\/10.1215\/S1152851705000074.","journal-title":"Neuro Oncol"},{"key":"1732_CR167","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","volume":"26","author":"SJ Kowalsky","year":"2018","unstructured":"Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS, Bartlett DL. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Mol Ther. 2018;26:2476\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.013.","journal-title":"Mol Ther"},{"key":"1732_CR168","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374:1325\u20136. https:\/\/doi.org\/10.1126\/science.abk3436.","journal-title":"Science"},{"key":"1732_CR169","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/ejhg.2015.252","volume":"24","author":"AM Jansen","year":"2016","unstructured":"Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG, Gomez-Garcia EB, Devilee P, et al. Combined mismatch repair and POLE\/POLD1 defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet. 2016;24:1089\u201392. https:\/\/doi.org\/10.1038\/ejhg.2015.252.","journal-title":"Eur J Hum Genet"},{"key":"1732_CR170","doi-asserted-by":"publisher","unstructured":"Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, et al. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell. 2021;39:109\u2013121 e105. https:\/\/doi.org\/10.1016\/j.ccell.2020.11.004.","DOI":"10.1016\/j.ccell.2020.11.004"},{"key":"1732_CR171","doi-asserted-by":"publisher","unstructured":"Devlin JR, Alonso JA, Ayres CM, Keller GLJ, Bobisse S, Vander Kooi CW, Coukos G, Gfeller D, Harari A, Baker BM. Structural dissimilarity from self drives neoepitope escape from immune tolerance. Nat Chem Biol. 2020;16:1269\u20131276. https:\/\/doi.org\/10.1038\/s41589-020-0610-1.","DOI":"10.1038\/s41589-020-0610-1"},{"key":"1732_CR172","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43856-024-00612-w","volume":"4","author":"A Claeys","year":"2024","unstructured":"Claeys A, Van den Eynden J. MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma. Commun Med (Lond). 2024;4:184. https:\/\/doi.org\/10.1038\/s43856-024-00612-w.","journal-title":"Commun Med (Lond)"},{"key":"1732_CR173","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033.","journal-title":"Cell"},{"key":"1732_CR174","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","volume":"70","author":"T Liu","year":"2021","unstructured":"Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B, Guo J, Wang S, Zhou P, Zhang H, et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. Gut. 2021;70:1965\u201377. https:\/\/doi.org\/10.1136\/gutjnl-2020-322196.","journal-title":"Gut"},{"key":"1732_CR175","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136. https:\/\/doi.org\/10.1038\/s41467-017-01062-w.","journal-title":"Nat Commun"},{"key":"1732_CR176","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6:827\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1545.","journal-title":"Cancer Discov"},{"key":"1732_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104816","volume":"97","author":"X Hu","year":"2023","unstructured":"Hu X, Deng X, Xie J, Tang H, Zou Y. Heterogeneous PD-L1 expression in metastases impacts immunotherapy response. EBioMedicine. 2023;97: 104816. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104816.","journal-title":"EBioMedicine"},{"key":"1732_CR178","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M Luksza","year":"2022","unstructured":"Luksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, Soares K, Amisaki M, Dobrin A, Hoyos D, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022;606:389\u201395. https:\/\/doi.org\/10.1038\/s41586-022-04735-9.","journal-title":"Nature"},{"key":"1732_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740427","volume":"11","author":"H Liang","year":"2021","unstructured":"Liang H, Huang J, Ao X, Guo W, Chen Y, Lu D, Lv Z, Tan X, He W, Jiang M, et al. TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol. 2021;11: 740427. https:\/\/doi.org\/10.3389\/fonc.2021.740427.","journal-title":"Front Oncol"},{"key":"1732_CR180","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1038\/s41467-021-24132-6","volume":"12","author":"BJ Burbach","year":"2021","unstructured":"Burbach BJ, O\u2019Flanagan SD, Shao Q, Young KM, Slaughter JR, Rollins MR, Street TJL, Granger VE, Beura LK, Azarin SM, et al. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. Nat Commun. 2021;12:3862. https:\/\/doi.org\/10.1038\/s41467-021-24132-6.","journal-title":"Nat Commun"},{"key":"1732_CR181","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1080\/08820139.2021.1973491","volume":"51","author":"S Ichimiya","year":"2022","unstructured":"Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yew PY, et al. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest. 2022;51:1498\u2013514. https:\/\/doi.org\/10.1080\/08820139.2021.1973491.","journal-title":"Immunol Invest"},{"key":"1732_CR182","doi-asserted-by":"publisher","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025. https:\/\/doi.org\/10.1038\/s41571-024-00984-x.","DOI":"10.1038\/s41571-024-00984-x"},{"key":"1732_CR183","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","volume":"2","author":"PMK Westcott","year":"2021","unstructured":"Westcott PMK, Sacks NJ, Schenkel JM, Ely ZA, Smith O, Hauck H, Jaeger AM, Zhang D, Backlund CM, Beytagh MC, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021;2:1071\u201385. https:\/\/doi.org\/10.1038\/s43018-021-00247-z.","journal-title":"Nat Cancer"},{"key":"1732_CR184","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22:433\u20138. https:\/\/doi.org\/10.1038\/nm.4051.","journal-title":"Nat Med"},{"key":"1732_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107827","volume":"31","author":"KE Pauken","year":"2020","unstructured":"Pauken KE, Godec J, Odorizzi PM, Brown KE, Yates KB, Ngiow SF, Burke KP, Maleri S, Grande SM, Francisco LM, et al. The PD-1 Pathway Regulates Development and Function of Memory CD8(+) T Cells following Respiratory Viral Infection. Cell Rep. 2020;31: 107827. https:\/\/doi.org\/10.1016\/j.celrep.2020.107827.","journal-title":"Cell Rep"},{"key":"1732_CR186","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu Z, Leet DE, Allesoe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27:515\u201325. https:\/\/doi.org\/10.1038\/s41591-020-01206-4.","journal-title":"Nat Med"},{"key":"1732_CR187","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372\u2013401. https:\/\/doi.org\/10.3322\/caac.21728.","journal-title":"CA Cancer J Clin"},{"key":"1732_CR188","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, Lamberti G, Di Federico A, Alessi J, Ferrara R, Sholl ML, Awad MM, Vokes N, Ricciuti B. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024;35:508\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.007.","journal-title":"Ann Oncol"},{"key":"1732_CR189","doi-asserted-by":"publisher","first-page":"21340","DOI":"10.1038\/s41598-022-25745-7","volume":"12","author":"L Xiong","year":"2022","unstructured":"Xiong L, He X, Wang L, Dai P, Zhao J, Zhou X, Tang H. Hypoxia-associated prognostic markers and competing endogenous RNA coexpression networks in lung adenocarcinoma. Sci Rep. 2022;12:21340. https:\/\/doi.org\/10.1038\/s41598-022-25745-7.","journal-title":"Sci Rep"},{"key":"1732_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781087","volume":"12","author":"ZY Zhu","year":"2021","unstructured":"Zhu ZY, Tang N, Wang MF, Zhou JC, Wang JL, Ren HZ, Shi XL. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma. Front Immunol. 2021;12: 781087. https:\/\/doi.org\/10.3389\/fimmu.2021.781087.","journal-title":"Front Immunol"},{"key":"1732_CR191","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtn.2020.08.030","volume":"22","author":"X Zhang","year":"2020","unstructured":"Zhang X, Shi M, Chen T, Zhang B. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020;22:298\u2013309. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.030.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1732_CR192","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682\u20137. https:\/\/doi.org\/10.1038\/nature04444.","journal-title":"Nature"},{"key":"1732_CR193","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/JIR.S349186","volume":"15","author":"L Xu","year":"2022","unstructured":"Xu L, Hu Y, Liu W. Pyroptosis-Mediated Molecular Subtypes are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer. J Inflamm Res. 2022;15:345\u201362. https:\/\/doi.org\/10.2147\/JIR.S349186.","journal-title":"J Inflamm Res"},{"key":"1732_CR194","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, Minker M, Li G, Fisher V, Sokol ES, et al. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discov. 2021;11:282\u201392. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0672.","journal-title":"Cancer Discov"},{"key":"1732_CR195","doi-asserted-by":"publisher","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259\u20131271 e1211. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001.","DOI":"10.1016\/j.cell.2017.10.001"},{"key":"1732_CR196","doi-asserted-by":"publisher","unstructured":"Pavelescu LA, Enache RM, Rosu OA, Profir M, Cretoiu SM, Gaspar BS. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25179659.","DOI":"10.3390\/ijms25179659"},{"key":"1732_CR197","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-21-0401","volume":"27","author":"K Chida","year":"2021","unstructured":"Chida K, Kawazoe A, Kawazu M, Suzuki T, Nakamura Y, Nakatsura T, Kuwata T, Ueno T, Kuboki Y, Kotani D, et al. A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H\/dMMR Gastrointestinal Tumors. Clin Cancer Res. 2021;27:3714\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0401.","journal-title":"Clin Cancer Res"},{"key":"1732_CR198","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36:1631\u201341. https:\/\/doi.org\/10.1200\/JCO.2017.76.8671.","journal-title":"J Clin Oncol"},{"key":"1732_CR199","doi-asserted-by":"publisher","unstructured":"Fridland S, Choi J, Nam M, Schellenberg SJ, Kim E, Lee G, Yoon N, Chae YK. Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB. J Immunother Cancer. 2021;9. https:\/\/doi.org\/10.1136\/jitc-2021-002551.","DOI":"10.1136\/jitc-2021-002551"},{"key":"1732_CR200","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.22.00364","volume":"41","author":"JT Topham","year":"2023","unstructured":"Topham JT, O\u2019Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, Banks KC, Quinn K, Renouf DJ, Jonker DJ, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol. 2023;41:485\u201396. https:\/\/doi.org\/10.1200\/JCO.22.00364.","journal-title":"J Clin Oncol"},{"key":"1732_CR201","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.6166","volume":"261","author":"J Zang","year":"2023","unstructured":"Zang J, Zhang R, Jin D, Xie F, Shahatiaili A, Wu G, Zhang Y, Zhao Z, Du P, Jia S, et al. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. J Pathol. 2023;261:198\u2013209. https:\/\/doi.org\/10.1002\/path.6166.","journal-title":"J Pathol"},{"key":"1732_CR202","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/gcc.23100","volume":"62","author":"EA Raiber-Moreau","year":"2023","unstructured":"Raiber-Moreau EA, Portella G, Butler MG, Clement O, Konigshofer Y, Hadfield J. Development and validation of blood tumor mutational burden reference standards. Genes Chromosomes Cancer. 2023;62:121\u201330. https:\/\/doi.org\/10.1002\/gcc.23100.","journal-title":"Genes Chromosomes Cancer"},{"key":"1732_CR203","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tranon.2019.09.008","volume":"13","author":"W Jing","year":"2020","unstructured":"Jing W, Li L, Zhang X, Wu S, Zhao J, Hou Q, Wu H, Ma W, Li S, Liu H, et al. Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease. Transl Oncol. 2020;13:245\u201353. https:\/\/doi.org\/10.1016\/j.tranon.2019.09.008.","journal-title":"Transl Oncol"},{"key":"1732_CR204","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21037\/tlcr.2018.08.01","volume":"7","author":"R Chaudhary","year":"2018","unstructured":"Chaudhary R, Quagliata L, Martin JP, Alborelli I, Cyanam D, Mittal V, Tom W, Au-Young J, Sadis S, Hyland F. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay. Transl Lung Cancer Res. 2018;7:616\u201330. https:\/\/doi.org\/10.21037\/tlcr.2018.08.01.","journal-title":"Transl Lung Cancer Res"},{"key":"1732_CR205","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-022-01280-w","volume":"15","author":"Y Han","year":"2022","unstructured":"Han Y, Wang D, Peng L, Huang T, He X, Wang J, Ou C. Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis. J Hematol Oncol. 2022;15:59. https:\/\/doi.org\/10.1186\/s13045-022-01280-w.","journal-title":"J Hematol Oncol"},{"key":"1732_CR206","doi-asserted-by":"publisher","unstructured":"Leader AM, Grout JA, Maier BB, Nabet BY, Park MD, Tabachnikova A, Chang C, Walker L, Lansky A, Le Berichel J, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell. 2021;39:1594\u20131609 e1512. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.009.","DOI":"10.1016\/j.ccell.2021.10.009"},{"key":"1732_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672020","volume":"11","author":"Q Duan","year":"2021","unstructured":"Duan Q, Tang C, Ma Z, Chen C, Shang X, Yue J, Jiang H, Gao Y, Xu B. Genomic Heterogeneity and Clonal Evolution in Gastroesophageal Junction Cancer Revealed by Single Cell DNA Sequencing. Front Oncol. 2021;11: 672020. https:\/\/doi.org\/10.3389\/fonc.2021.672020.","journal-title":"Front Oncol"},{"key":"1732_CR208","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s42003-023-04856-5","volume":"6","author":"JW Loh","year":"2023","unstructured":"Loh JW, Lee JY, Lim AH, Guan P, Lim BY, Kannan B, Lee ECY, Gu NX, Ko TK, Ng CC, et al. Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma. Commun Biol. 2023;6:461. https:\/\/doi.org\/10.1038\/s42003-023-04856-5.","journal-title":"Commun Biol"},{"key":"1732_CR209","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021;32:1626\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.016.","journal-title":"Ann Oncol"},{"key":"1732_CR210","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","volume":"9","author":"PJ Volders","year":"2025","unstructured":"Volders PJ, Aftimos P, Dedeurwaerdere F, Martens G, Canon JL, Beniuga G, Froyen G, Van Huysse J, De Pauw R, Prenen H, et al. A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer. NPJ Precis Oncol. 2025;9:66. https:\/\/doi.org\/10.1038\/s41698-025-00858-0.","journal-title":"NPJ Precis Oncol"},{"key":"1732_CR211","doi-asserted-by":"publisher","unstructured":"Botticelli A, Scagnoli S, Conte P, Cremolini C, Ascierto PA, Cappuzzo F, Aglietta M, Mazzuca F, Capoluongo E, Blandino G, et al. LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy. Annals of Oncology. 2024;35. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2245.","DOI":"10.1016\/j.annonc.2024.08.2245"},{"key":"1732_CR212","doi-asserted-by":"publisher","unstructured":"Botticelli A, Scagnoli S, Guarneri V, Del Mastro L, Puglisi F, Pisegna S, Crimini E, Verkhovskaia S, Biffoni M, Conte PF, et al. 15P The ROME trial: Personalized target therapy and immunotherapy in the breast cancer subgroup. ESMO Open. 2025;10.\u00a0https:\/\/doi.org\/10.1016\/j.esmoop.2025.104569.","DOI":"10.1016\/j.esmoop.2025.104569"},{"key":"1732_CR213","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376:2415\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613493.","journal-title":"N Engl J Med"},{"key":"1732_CR214","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"key":"1732_CR215","doi-asserted-by":"publisher","unstructured":"Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J Immunother Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-004668.","DOI":"10.1136\/jitc-2022-004668"},{"key":"1732_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188447","volume":"1874","author":"DY Lizardo","year":"2020","unstructured":"Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer. 2020;1874: 188447. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188447.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1732_CR217","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1526613","volume":"7","author":"J Budczies","year":"2018","unstructured":"Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Gyorffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncoimmunology. 2018;7: e1526613. https:\/\/doi.org\/10.1080\/2162402X.2018.1526613.","journal-title":"Oncoimmunology"},{"key":"1732_CR218","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1470-2045(22)00783-5","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023;24:151\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(22)00783-5.","journal-title":"Lancet Oncol"},{"key":"1732_CR219","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pilie PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006.","journal-title":"Ann Oncol"},{"key":"1732_CR220","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.hbpd.2022.08.002","volume":"21","author":"ZF Lin","year":"2022","unstructured":"Lin ZF, Qin LX, Chen JH. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int. 2022;21:413\u20139. https:\/\/doi.org\/10.1016\/j.hbpd.2022.08.002.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1732_CR221","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1801946.","journal-title":"N Engl J Med"},{"key":"1732_CR222","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1571\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370.","journal-title":"JAMA Oncol"},{"key":"1732_CR223","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023;41:15\u201340. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.013.","journal-title":"Cancer Cell"},{"key":"1732_CR224","doi-asserted-by":"publisher","unstructured":"Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, Maiorino L, White FM, Irvine DJ, Litchfield K, et al. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-010249.","DOI":"10.1136\/jitc-2024-010249"},{"key":"1732_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.06.007","author":"E Jaeckel","year":"2025","unstructured":"Jaeckel E, Friedman SL, Hudecek M, Protzer U. Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.007.","journal-title":"J Hepatol"},{"key":"1732_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112827","volume":"42","author":"Y Chen","year":"2023","unstructured":"Chen Y, Mason GH, Scourfield DO, Greenshields-Watson A, Haigh TA, Sewell AK, Long HM, Gallimore AM, Rizkallah P, MacLachlan BJ, et al. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4(+) T cell immunity. Cell Rep. 2023;42: 112827. https:\/\/doi.org\/10.1016\/j.celrep.2023.112827.","journal-title":"Cell Rep"},{"key":"1732_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200978","volume":"33","author":"A Goloudina","year":"2025","unstructured":"Goloudina A, Le Chevalier F, Authie P, Charneau P, Majlessi L. Shared neoantigens for cancer immunotherapy. Mol Ther Oncol. 2025;33: 200978. https:\/\/doi.org\/10.1016\/j.omton.2025.200978.","journal-title":"Mol Ther Oncol"},{"key":"1732_CR228","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s12967-025-06478-3","volume":"23","author":"A Mauriello","year":"2025","unstructured":"Mauriello A, Cavalluzzo B, Ragone C, Tagliamonte M, Buonaguro L. Shared neoantigens\u2019 atlas for off-the-shelf cancer vaccine development. J Transl Med. 2025;23:558. https:\/\/doi.org\/10.1186\/s12967-025-06478-3.","journal-title":"J Transl Med"},{"key":"1732_CR229","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/2326-6066.CIR-22-0621","volume":"11","author":"G Bedran","year":"2023","unstructured":"Bedran G, Gasser HC, Weke K, Wang T, Bedran D, Laird A, Battail C, Zanzotto FM, Pesquita C, Axelson H, et al. The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides. Cancer Immunol Res. 2023;11:747\u201362. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0621.","journal-title":"Cancer Immunol Res"},{"key":"1732_CR230","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12865-016-0156-x","volume":"17","author":"S Wang","year":"2016","unstructured":"Wang S, Guo L, Liu D, Liu W, Wu Y. HLAsupE: an integrated database of HLA supertype-specific epitopes to aid in the development of vaccines with broad coverage of the human population. BMC Immunol. 2016;17:17. https:\/\/doi.org\/10.1186\/s12865-016-0156-x.","journal-title":"BMC Immunol"},{"key":"1732_CR231","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13073-023-01275-3","volume":"16","author":"G Rospo","year":"2024","unstructured":"Rospo G, Chila R, Matafora V, Basso V, Lamba S, Bartolini A, Bachi A, Di Nicolantonio F, Mondino A, Germano G, et al. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer. Genome Med. 2024;16:15. https:\/\/doi.org\/10.1186\/s13073-023-01275-3.","journal-title":"Genome Med"},{"key":"1732_CR232","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.annonc.2022.03.011","volume":"33","author":"AS Venkataramany","year":"2022","unstructured":"Venkataramany AS, Schieffer KM, Lee K, Cottrell CE, Wang PY, Mardis ER, Cripe TP, Chandler DS. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities. Ann Oncol. 2022;33:578\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.011.","journal-title":"Ann Oncol"},{"key":"1732_CR233","doi-asserted-by":"publisher","unstructured":"Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, et al. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology. 2021;161:1288\u20131302 e1213. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.073.","DOI":"10.1053\/j.gastro.2021.06.073"},{"key":"1732_CR234","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1038\/s41467-023-39570-7","volume":"14","author":"C Tretter","year":"2023","unstructured":"Tretter C, de Andrade Kratzig N, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, et al. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification. Nat Commun. 2023;14:4632. https:\/\/doi.org\/10.1038\/s41467-023-39570-7.","journal-title":"Nat Commun"},{"key":"1732_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122643","volume":"634","author":"F Wang","year":"2023","unstructured":"Wang F, Sangfuang N, McCoubrey LE, Yadav V, Elbadawi M, Orlu M, Gaisford S, Basit AW. Advancing oral delivery of biologics: Machine learning predicts peptide stability in the gastrointestinal tract. Int J Pharm. 2023;634: 122643. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122643.","journal-title":"Int J Pharm"},{"key":"1732_CR236","doi-asserted-by":"publisher","unstructured":"Strazar M, Park J, Abelin JG, Taylor HB, Pedersen TK, Plichta DR, Brown EM, Eraslan B, Hung YM, Ortiz K, et al. HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery. Immunity. 2023;56:1681\u20131698 e1613. https:\/\/doi.org\/10.1016\/j.immuni.2023.05.009.","DOI":"10.1016\/j.immuni.2023.05.009"},{"key":"1732_CR237","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1158\/2159-8290.CD-24-0751","volume":"14","author":"CM Arends","year":"2024","unstructured":"Arends CM, Jaiswal S. Gene-Specific Machine Learning Models to Classify Driver Mutations in Clonal Hematopoiesis. Cancer Discov. 2024;14:1581\u20133. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0751.","journal-title":"Cancer Discov"},{"key":"1732_CR238","doi-asserted-by":"publisher","unstructured":"He LN, Li H, Du W, Fu S, Luo L, Chen T, Zhang X, Chen C, Jiang Y, Wang Y, et al. Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy. iScience. 2023;26:107058. https:\/\/doi.org\/10.1016\/j.isci.2023.107058.","DOI":"10.1016\/j.isci.2023.107058"},{"key":"1732_CR239","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41587-024-02210-6","volume":"43","author":"Z Moravec","year":"2025","unstructured":"Moravec Z, Zhao Y, Voogd R, Cook DR, Kinrot S, Capra B, Yang H, Raud B, Ou J, Xuan J, et al. Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening. Nat Biotechnol. 2025;43:214\u201322. https:\/\/doi.org\/10.1038\/s41587-024-02210-6.","journal-title":"Nat Biotechnol"},{"key":"1732_CR240","doi-asserted-by":"publisher","unstructured":"Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371. https:\/\/doi.org\/10.1126\/science.abc8697.","DOI":"10.1126\/science.abc8697"},{"key":"1732_CR241","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41587-024-02161-y","volume":"43","author":"CL Tan","year":"2025","unstructured":"Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, et al. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy. Nat Biotechnol. 2025;43:134\u201342. https:\/\/doi.org\/10.1038\/s41587-024-02161-y.","journal-title":"Nat Biotechnol"},{"key":"1732_CR242","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s43018-023-00548-5","volume":"4","author":"AI Kraemer","year":"2023","unstructured":"Kraemer AI, Chong C, Huber F, Pak H, Stevenson BJ, Muller M, Michaux J, Altimiras ER, Rusakiewicz S, Simo-Riudalbas L, et al. The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. Nat Cancer. 2023;4:608\u201328. https:\/\/doi.org\/10.1038\/s43018-023-00548-5.","journal-title":"Nat Cancer"},{"key":"1732_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122290","volume":"301","author":"R Li","year":"2023","unstructured":"Li R, Hao Y, Roche K, Chen G, Pan W, Wang AZ, Min Y. Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy. Biomaterials. 2023;301: 122290. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122290.","journal-title":"Biomaterials"},{"key":"1732_CR244","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202411330","volume":"37","author":"KM Au","year":"2025","unstructured":"Au KM, Swinnea JS, Wang AZ. Intratumoral Injectable Redox-Responsive Immune Niche Improves the Abscopal Effect in Radiotherapy. Adv Mater. 2025;37: e2411330. https:\/\/doi.org\/10.1002\/adma.202411330.","journal-title":"Adv Mater"},{"key":"1732_CR245","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","volume":"10","author":"AJ Anandappa","year":"2020","unstructured":"Anandappa AJ, Wu CJ, Ott PA. Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020;10:185\u201397. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0790.","journal-title":"Cancer Discov"},{"key":"1732_CR246","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12885-022-09683-1","volume":"22","author":"Y Jin","year":"2022","unstructured":"Jin Y, Lin C, Shi X, He Q, Yan J, Yu X, Chen M. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. BMC Cancer. 2022;22:586. https:\/\/doi.org\/10.1186\/s12885-022-09683-1.","journal-title":"BMC Cancer"},{"key":"1732_CR247","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11604-021-01230-5","volume":"40","author":"N Ota","year":"2022","unstructured":"Ota N, Yoshimoto Y, Darwis NDM, Sato H, Ando K, Oike T, Ohno T. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol. 2022;40:534\u201341. https:\/\/doi.org\/10.1007\/s11604-021-01230-5.","journal-title":"Jpn J Radiol"},{"key":"1732_CR248","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202401354","volume":"13","author":"M He","year":"2024","unstructured":"He M, Xu W, Dan Y, Pan Y, Li Y, Chen M, Dong CM. Mannosylated Fluoropolypeptide Nanovaccines Remodeling Tumor Immunosuppressive Microenvironment to Achieve Highly Potent Cancer Immunotherapy. Adv Healthc Mater. 2024;13: e2401354. https:\/\/doi.org\/10.1002\/adhm.202401354.","journal-title":"Adv Healthc Mater"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01732-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01732-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01732-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:03:06Z","timestamp":1756857786000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01732-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":248,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01732-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}